{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-127.0","upperLimit":"41.0","value":"6.00"},{"groupId":"OG001","lowerLimit":"-64.0","upperLimit":"50.0","value":"-8.50"},{"groupId":"OG002","lowerLimit":"-11.0","upperLimit":"26.0","value":"1.00"},{"groupId":"OG003","lowerLimit":"-51.0","upperLimit":"40.0","value":"-2.00"},{"groupId":"OG004","lowerLimit":"-59.0","upperLimit":"31.0","value":"0.00"},{"groupId":"OG005","lowerLimit":"-41.0","upperLimit":"115.0","value":"-4.00"},{"groupId":"OG006","lowerLimit":"-11.0","upperLimit":"15.0","value":"-1.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"33"},{"groupId":"OG006","value":"12"}],"units":"Participants"}],"description":"Anti-tumor activity measured by maximum reduction among available post-baseline sum of lesion measurements was not planned to be collected for the dose escalation part.","dispersionType":"Full Range","groups":[{"description":"Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG000","title":"Dose Expansion Part: Bladder Cancer"},{"description":"Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG001","title":"Dose Expansion Part: Cervical Cancer"},{"description":"Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG002","title":"Dose Expansion Part: Endometrial Cancer"},{"description":"Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG003","title":"Dose Expansion Part: Esophageal Cancer"},{"description":"Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG004","title":"Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)"},{"description":"Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG005","title":"Dose Expansion Part: Ovarian Cancer"},{"description":"Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.","id":"OG006","title":"Dose Expansion Part: Prostate Cancer"}],"paramType":"MEDIAN","populationDescription":"The number of participants analyzed includes all participants with baseline and one post-baseline evaluable tumor assessment","reportingStatus":"POSTED","timeFrame":"Day 1 to end of follow-up, up to a maximum of 60 weeks","title":"Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction Among Available Post-Baseline Sum of Lesion Measurements","type":"SECONDARY","unitOfMeasure":"millimeter(s)"}